Answers are grounded in this paper and cite their sources.
Demonstrates improved antigen delivery and humoral responses via peptide-targeted Langerhans cells, indicating new vaccine strategies.
Langerhans cells (LCs) are specialized antigen-presenting cells residing in the epidermis. LCs express the C-type lectin receptor CD207, which mediates antigen uptake and internalization. Because epidermal LCs encounter antigens at the skin surface and regulate subsequent immune responses, CD207 provides a rational molecular target for skin-based antigen delivery strategies. In this study, we performed ribosome display using a structurally constrained cyclic peptide library to identify mCD207-binding peptides. After three rounds of bio-panning, three candidate peptide-EGFP fusion constructs exhibited micromolar affinity for recombinant mCD207, with the strongest binder showing a KD of approximately 0.3 μM. Peptide 2 and peptide 3 selectively bound to mCD207-expressing mammalian cells and primary mouse LCs. Fusion of peptide 3 to a model antigen enhanced antigen delivery to LCs and increased antigen-specific serum IgG levels following intradermal immunization in mice. These findings identify ribosome display-derived mCD207-targeting peptides as novel molecular tools for selective antigen delivery to epidermal LCs.
No takes yet. Share an insight, caveat, or question.
Yokoyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: